Abstract
Pharmacological effects were recorded and time course for receptor binding in brain was followed by positron emission tomography after IV injection of the selective D1-dopamine receptor antagonist SCH 23390 in four healthy subjects in doses of 310–810 µg. Akathisia, the syndrome of motor restlessness, appeared after the three highest doses. The akathisia was transient and occurred only when [11C]SCH 23390 binding in the basal ganglia was at a high level with a central D1-dopamine receptor occupancy of 45–59%. The D2-dopamine receptor antagonist [11C]raclopride was injected IV into 20 healthy subjects and 13 schizophrenic patients. Akathisia appeared in 14 healthy subjects and 7 patients and coincided with maximal [11C]raclopride binding in the basal ganglia. The findings for [11C]raclopride and [11C]SCH 23390 are the first demonstration of a relationship between time courses for radioligand binding in the human brain and simultaneously induced pharmacological effects.
Similar content being viewed by others
References
Adler LA, Angrist B, Reiter S, Rotrosen J (1989) Neuroleptic-induced akathisia: a review. Psychopharmacology 97:1–11
Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676
Barnes TRE, Braude WM (1985) Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 42:874–878
Bergström M, Boethius J, Eriksson L, Greitz T, Ribbe T, Widen L (1981) Head fixation device for reproducible positron alignment in transmission CT and positron emission tomography. J Comput Assist Tomogr 8:74–87
Bing R (1923) Über einige bemerkenswerte Begleiterscheinigungen der extrapyramidalen Rigidität (Akathesie — Mocrographie — Kinesia paradoxica) Schweiz Med Wochenschr 53:167–171
Casey DE (1992) Dopamine D1 and D2 antagonists in neurolepticnaive monkeys. Psychophamacology 107:18–22
Cortes R, Camps M, Gueye B, Probst A, Palacios J (1989) Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res 483:30–38
Farde L, Hall H, Ehrin E, Sedvall G (1986) Quantitative analysis of dopamine-D-2 receptor binding in the living human brain by positron emission tomography. Science 231:258–261
Farde L, Halldin C, Stone-Elander S, Sedvall G (1987) PET-analysis of human dopamine receptor subtypes using [11C]-SCH 23390 and [11C]-raclopride. Psychopharmacology 92:278–284
Farde L, Grind M, Nilsson M-I, Ogenstad S, Sedvall G (1988a) Remoxipride — a new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers Psychopharmacology 95:157–161
Farde L, Wiesel F-A, Halldin C, Sedvall G (1988b) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71–78
Farde L, von Bahr C, Wahlen A, Widman M, Nilsson L (1989a) The new selective D2-dopamine receptor antagonist raclopride — pharmacokinetics, effects and safety in healthy males. Int Clin Psychopharmacol 4:116–126
Farde L, Eriksson L, Blomquist G, Halldin C (1989b) Kinetic analysis of11C-ralcopride binding to D2-dopamine receptors in the living human brain by PET — a comparison to the saturation analysis. J Cereb Blood Flow Metab 9:696–708
Farde L, Wiesel FA, Halldin C, Stone-Elander S, Nordström AL, Hall H, Sedvall G (1990) D2-dopamine receptor characteristics in neuroleptic-naive patients with schizophrenia — a PET study with [11C]raclopride. Arch Gen Psychiatry 47:213–219
Freyhan FA (1957) Psychomotility and parkinsonism in treatment with neuroleptic drugs. Arch Neurol Psychiatry 78:465–472
Frost J, Smith A, Kuhar M, Dannals R, Wagner H (1987) In vivo binding of 3H-N-methylspiperone to dopamine and serotonin receptors. Life Sci 40:987–995
Gessa GL, Canu A, Del Zompo M, Burrai C, Serra G (1991) Lack of acute antipsychotic effect of SCH 23390, a selective dopamine D1 receptor antagonist. Lancet 337:854–855
Hall H, Farde L, Sedvall G (1988) Human dopamine receptor subtypes — In vitro binding analysis using 3H-SCH 23390 and 3H-raclopride. J Neural Transmission 73:7–21
Halldin C, Stone, Elander S, Farde L, Ehrin E, Fasth KJ, Långström B, Sedvall G (1986) Preparation of [11C]labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Int J Appl Radiat Isot 37:1039–1043
Halldin C, Farde L, Högberg T, Hall H, Ström P, Ohlberger A, Solin O (1991) A comparative PET study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. Nucl Med Biol 18:871–881
Haskovec L (1903) Nouvelles remarques sur l'akathisie. Nouv Iconograph Salpetrière 16:287–296
Hodge JR (1959) Akathisia: the syndrome of motor restlessness. Am J Psychiatry 116:337–338
Hyttel J (1983) SCH 23390 — the first selective dopamine-D1 antagonist. Eur J Pharmacol 91:153–154
Iorio LC (1981) SCH 23390. A benzazepine with atypical effects on dopaminergic systems. Pharmacologist 23:136
Joyce J, Lexow N, Bird E, Winokur A (1988) Organization of dopamine D1 and D2 receptors in human striatum. Synapse 2:546–557
Kebabian JW, Petzold GL, Greengard P (1972) Dopamine sensitive adenylate cyclase in the caudate nucleus of rat brain. and its similarity to the “dopamine receptor”. Proc Natl Acad Sci USA 69:2145–2149
Kekich WA (1978) Violence as a manifestation of akathisia. JAMA 240:2185
Köhler C, Hall H, Ögren S, Gawell L (1985) Specific in vitro and in vivo binding of 3H-raclopride. Biochem Pharmacol 34:2251–2259
Litton J, Bergström L, Eriksson C, Bohm C, Blomquist G, Kesselberg M (1984) Performance study of the PC-384 positron camera system for emission tomography of the brain. J Comp Assist Tomogr 8:74–87
Ögren S, Hall H, Köhler C, Magnusson O, Sjöstrand S (1986) The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions Psychopharmacology 90:289
Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717–719
Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146–151
Van Putten T, May PRA, Marder SR, Wittman LA (1981) Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38:187
Waddington JL, O'Boyle KM (1989) Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D-1 antagonist. Pharmacol Ther 43[1]:1–527
Wilson SA, Kinnier (1940) In: Bruce AN (ed) Neurology, vols 1 and 2. A William Wood Book. Williams and Wilkins, Baltimore, p 118 (vol 1) and p 793 (vol 2)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Farde, L. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans — a PET study with [11C]SCH 23390 and [11C]raclopride. Psychopharmacology 107, 23–29 (1992). https://doi.org/10.1007/BF02244961
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244961